JPMorgan lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 2,000 GBp from 2,400 GBp and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HKMPF:
- Hikma Cancels Further Shares as $250m Buyback Gathers Pace
- Hikma Updates Market on Current Voting Share Capital
- Hikma Advances $250m Buyback With New Share Purchase and Planned Cancellation
- Hikma launches $250m buyback with first £1.2m share purchase
- Hikma Pharmaceuticals Balances Profit Strength With Injectables Reset